Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment.
Chronic myeloid leukemia (CML) is triggered by the BCR-ABL oncogene. Imatinib is the first-line treatment of CML; however imatinib resistance and intolerance have been detected in many patients. Therefore, new therapeutic approaches are required. The present work aimed at the development and application of transferrin receptor (TrfR) targeted liposomes co-encapsulating anti-BCR-ABL siRNA and imatinib at different molar ratios. The encapsulation yields and drug loading of each molecule was evaluated. Anti-leukemia activity of the developed formulations co-encapsulating siRNA and imatinib and of the combination of Trf-liposomes carrying siRNA and free imatinib under two different treatment schedules of pre-sensitization was assessed. The results obtained demonstrate that the presence of imatinib significantly decreases the encapsulation yields of siRNA, whereas imatinib encapsulation yields are increased by the presence of siRNA. Cytotoxicity assays demonstrate that the formulations co-encapsulating siRNA and imatinib promote a 3.84-fold reduction on the imatinib IC(50) (from 3.49 to 0.91 µM), whereas a 8.71-fold reduction was observed for the pre-sensitization protocols (from 42.7 to 4.9 nM). It was also observed that the formulations with higher siRNA to imatinib molar ratios promote higher cell toxicity. Thus, the present work describes a novel triple targeting strategy with one single system: cellular targeting (through the targeting ligand, transferrin) and molecular targeting at the BCR-ABL mRNA and Bcr-Abl protein level.
Mendonça
Liliana S
LS
Faculty of Pharmacy, Laboratory of Pharmaceutical Technology, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
Moreira
João N
JN
de Lima
Maria C Pedroso
MC
Simões
Sérgio
S
D000970:Antineoplastic Agents / Q000378:metabolism*; D001549:Benzamides; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000378:metabolism / Q000493:pharmacokinetics*; D006801:Humans; D000068877:Imatinib Mesylate; D020128:Inhibitory Concentration 50; D008081:Liposomes / Q000378:metabolism / Q000493:pharmacokinetics*; D016374:Oncogene Proteins v-abl / Q000032:analysis / Q000235:genetics; D010879:Piperazines / Q000378:metabolism / Q000493:pharmacokinetics*; D051562:Proto-Oncogene Proteins c-bcr / Q000032:analysis / Q000235:genetics; D011743:Pyrimidines / Q000378:metabolism / Q000493:pharmacokinetics*; D034741:RNA, Small Interfering / Q000378:metabolism / Q000493:pharmacokinetics*; D014168:Transferrin / Q000378:metabolism*
D000970:Antineoplastic Agents; D001549:Benzamides; D004337:Drug Carriers; D008081:Liposomes; D016374:Oncogene Proteins v-abl; D010879:Piperazines; D011743:Pyrimidines; D034741:RNA, Small Interfering; D014168:Transferrin; D000068877:Imatinib Mesylate; C496613:BCR protein, human; D051562:Proto-Oncogene Proteins c-bcr